Natalizumab is a humanized recombinant monoclonal antibody against alpha4-intigrin. In a large phase III study on relapsing-remitting MS Natalizumab reduced the relapse rate by 68% and the appearance of permanent neurological deficits by 42%. Currently, Natalizumab is the most effective disease-modifying treatment of relapsing-remitting MS. The clinical use of the treatment will be restricted initially due to uncertainty about the risk of opportunistic infections in long term treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
[natalizumab tysabri]
4
tysabri] natalizumab
4
natalizumab humanized
4
humanized recombinant
4
recombinant monoclonal
4
monoclonal antibody
4
antibody alpha4-intigrin
4
alpha4-intigrin large
4
large phase
4
phase iii
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!